Penicillamine-induced proteinuria: Risk factors

Seminars in Arthritis and Rheumatism

Volumn 15, Issue 4, 1986, Pages 282-287

  Stein, Howard B ^a   Schroeder, M L ^b   Dillon, Aileen M ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXTROPROPOXYPHENE; GOLD SALT; HLA B8 ANTIGEN; HLA DR3 ANTIGEN; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; PENICILLAMINE; PREDNISONE; TOLMETIN;

ADVERSE DRUG REACTION; DRUG RECHALLENGE; DRUG THERAPY; HEREDITY; HLA SYSTEM; HUMAN; INTOXICATION; JOINT; KIDNEY; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; NERVOUS SYSTEM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PROTEINURIA; RHEUMATOID ARTHRITIS; THERAPY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; DISEASE SUSCEPTIBILITY; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HLA-B8 ANTIGEN; HLA-DR3 ANTIGEN; HUMAN; MALE; MIDDLE AGE; PENICILLAMINE; PROTEINURIA;

EID: 0022913124     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(86)90023-5     Document Type: Article

References (50)

1. Adverse effects of penicillamine in rheumatoid arthritis
2. The relationship between d-penicillamine-induced proteinuria and prior gold nephropathy
3. Penicillamine in rheumatic diseases: A prospective study of tolerance and efficacy
4. Sequential gold and penicillamine therapy in rheumatoid arthritis. Comparative study of effectiveness and toxicity and review of the literature
5. Influence of previous gold toxicity on subsequent development of penicillamine toxicity
6. An assessment of penicillamine therapy in rheumatoid arthritis and the influence of previous gold therapy
7. HLA-DR antigens and toxic reactions to sodium aurothiomalate and d-penicillamine in patients with rheumatoid arthritis
8. HLA system and side effects of gold salts and d-penicillamine treatment of rheumatoid arthritis
9. A systematic survey of HLA-A, B, C and D antigens and drug toxicity in rheumatoid arthritis
10. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis
11. HLA-DR antigens and proteinuria induced by aurothioglucose and d-penicillamine in patients with rheumatoid arthritis
12. Penicillamine nephropathy and iron
13. Factors affecting the development of penicillamine side-effects
14. NIAID: NIH lymphocyte microcytotoxicity technique
15. HL-A antigens and disease: Statistical and genetical considerations
16. Penicillamine and the nephrotic syndrome. Results in patients with hepatolenticular degeneration
17. Nephrotoxic effects of penicillamine in cystinuria
18. Effect of d-penicillamine on serum immunoglobulins and rheumatoid factor
19. Treatment of lead poisoning with oral penicillamine
20. Nephropathy induced by d-penicillamine
21. Drug-induced proteinuria
22. Penicillamine in rheumatoid disease: A long-term study
23. Immunopathology of penicillamine-induced glomerular disease
24. Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study
25. Treatment of rheumatoid arthritis with penicillamine
26. The toxicity pattern of d-penicillamine: A guide to its use in rheumatoid arthritis
27. Penicillamine nephropathy
28. Proteinuria in rheumatoid arthritis—Drug-induced or amyloid?
29. Proteinuria in d-penicillamine-treated rheumatoid arthritis
30. Reversible renal failure and nephrotic syndrome associated with nonsteroidal antiinflammatory drugs
31. Simultaneous occurrence of perimembranous glomerulonephritis and glomerular amyloidosis
32. Renal disease in rheumatoid arthritis
33. Maintenance dose of penicillamine in rheumatoid arthritis: A comparison between a standard and a response-related flexible regimen
34. Toxicity of d-penicillamine in rheumatoid arthritis
35. The glomerular filtration rate during penicillamine therapy in rheumatoid arthritis
36. Penicillamine-induced acute renal failure
37. Resumption of treatment with penicillamine after proteinuria
38. Nephropathy induced by d-penicillamine
39. Immunhistologische befunde an nierenbiopsien bei morbus Wilson
40. Fatal renal vasculitis and minimal change glomerulonephritis complicating treatment with penicillamine
41. d-penicillamine nephropathy, circulating immune complexes and antibodies
42. Precipitating autoantibody to a ubiquitous tissue antigen: Association with rheumatoid arthritis treated with sodium aurothiomalate or d-penicillamine
43. d-penicillamine induced Goodpasture's syndrome in Wilson's disease
44. Goodpasture syndrome and d-penicillamine
45. Penicillamine-induced “Goodpasture's syndrome”: Successful treatment of a fulminant case
46. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis
47. DR antigens and gold toxicity in white rheumatoid arthritis patients
48. Strong association between idiopathic membranous nephropathy and HLA-DRW3
49. Deficient sulphoxidation status and d-penicillamine toxicity